To assess the in vivo anti-hepatocellular carcinoma efficacy of the PCSK9 inhibitor, luci-Hepa1-6 cells were intraportally injected into the left hepatic lobes of male C57BL/6J mice aged 6 to 8 weeks (Figure 3A), and bioluminescence intensity in the different groups were measured based on in vivo imaging. This evidence concerns the gene PCSK9 and hepatocellular carcinoma.